AVROBIO, a clinical-stage biotechnology company developing transformative cell and gene therapies targeting cancer and rare diseases, has made three senior appointments. Joining the firm’s leadership team are Kim Warren, Head of Operations, Chris Mason, Chief Science Officer, and Deanna Petersen, Chief Business Officer.
According to an official statement, the company’s priority is to accelerate development of two novel cell and gene therapies pioneered within the labs of Christopher Paige and Jeffrey Medin (now at the Medical College of Wisconsin) at the University Health Network (UHN) in Toronto, ON. Phase 1 programs will be in the clinic by early to mid-2016 in both acute myeloid leukaemia (AML) and Fabry disease. The company will simultaneously work to expand its proprietary cell and gene therapy platform to treat additional indications.
“We are very proud to carry forward the ground-breaking work of our founding scientists with investment from Atlas Venture and partnership with the Centre for Commercialization of Regenerative Medicine (CCRM),” commented Geoff MacKay, AVROBIO’s President and Chief Executive Officer.
“We look forward to very near-term generation of clinical data in 2016 from both phase 1 trials” said Bruce Booth, Partner at Atlas Venture and member of AVROBIO’s Board of Directors.
AVROBIO has offices in both Toronto, ON and Cambridge, MA. The firm’s board of directors consists of MacKay, Paige and Booth.